25
|
Insulin Like Growth Factor-1 (IGF-1)
|
Protein
|
Humans
|
Dowregulated (Preintervention: 232.7 ± 20.6 ng/mL Vs Postintervention: 16.92 ± 23.3 ng/mL)
|
Predictive
|
Prostate Cancer patients pre and post treatment with Lycopene
|
p=0.0002
|
Plasma
|
11489752
|
26
|
Insulin Like Growth Factor Binding Protein 3 (IGFBP-3)
|
Protein
|
Humans
|
Dowregulated (Preintervention: 5230 ± 244 ng/mL Vs Postintervention: 3924 ± 298 ng/mL)
|
Predictive
|
Prostate Cancer patients pre and post treatment with Lycopene
|
p=0.0002
|
Plasma
|
11489752
|
254
|
C-reactive protein (CRP)
|
Protein
|
Humans
|
Increased in Overall Survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.0001
|
Plasma
|
18428198
|
255
|
C-reactive protein (CRP)
|
Protein
|
Humans
|
Increased in Overall Survival
|
Prognostic
|
PSA Decline Vs No PSA decline
|
p=0.0068
|
Plasma
|
18428198
|
350
|
Transforming growth factor-β1 (TGF-β1)
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
p<0.001
|
Plasma
|
18559597
|
351
|
soluble IL-6 receptor (sIL-6R)
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
p<0.001
|
Plasma
|
18559597
|
352
|
IL-6
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
p<0.001
|
Plasma
|
18559597
|
353
|
Vascular endothelial growth factor (VEGF)
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
Univariate: p= 0.002; Multivariate: p=0.008
|
Plasma
|
18559597
|
354
|
Vascular cell adhesion molecule-1 (VCAM-1)
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
p<0.001
|
Plasma
|
18559597
|
355
|
Endoglin
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
Univariate: p<0.001Multivariate: p=0.002
|
Plasma
|
18559597
|
356
|
Urokinase-type plasminogen activator (uPA)
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
p<0.001
|
Plasma
|
18559597
|
357
|
uPA receptor (uPAR)
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
Univariate: p<0.001; Multivariate: p=0.05
|
Plasma
|
18559597
|
358
|
TGF-β1 + sIL-6R + IL-6 + VCAM-1 + VEGF + endoglin + uPA + PAI-1 + uPAR
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
NA
|
Plasma
|
18559597
|
359
|
TGF-β1 + sIL-6R + IL-6 + VCAM-1 + VEGF + endoglin + uPA
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
NA
|
Plasma
|
18559597
|
417
|
Transforming growth factor-b1
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
Univariate: p<0.001; Multivariate: p=0.003
|
Plasma
|
19229851
|
418
|
Interleukin-6 soluble receptor ((IL-6sR)
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
Univariate: p<0.001; Multivariate: p=0.001
|
Plasma
|
19229851
|
419
|
Interleukin-6 (IL-6)
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
Univariate: p<0.001
|
Plasma
|
19229851
|
420
|
Vascular cell adhesion molecular 1 (VCAM 1)
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
p<0.001
|
Plasma
|
19229851
|
421
|
Vascular endothelial growth factor (VEGF)
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
p=0.002
|
Plasma
|
19229851
|
422
|
Endoglin
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
p<0.001
|
Plasma
|
19229851
|
423
|
Urokinase-type plasminogen activator (uPA)
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
Univariate: p<0.001; Multivariate: p=0.036
|
Plasma
|
19229851
|
424
|
Urokinase-type plasminogen activator receptor (uPAR)
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
p<0.001
|
Plasma
|
19229851
|
425
|
Gleason sum +TGFB1+ IL-6sR +VCAM1+uPA
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
NA
|
Plasma
|
19229851
|
592
|
placental growth factor (PIGF)
|
Protein
|
Humans
|
Downregulated in Docetaxel + Imatinib arm
|
Predictive
|
Docetaxel + placebo VS Docetaxel + imatinib
|
p<0.001
|
Plasma
|
21323568
|
593
|
soluble c-kit
|
Protein
|
Humans
|
Downregulated in Docetaxel + Imatinib arm
|
Predictive
|
Docetaxel + placebo VS Docetaxel + imatinib
|
p<0.001
|
Plasma
|
21323568
|
594
|
VEGF
|
Protein
|
Humans
|
Downregulated in Docetaxel + Imatinib arm
|
Predictive
|
Docetaxel + placebo VS Docetaxel + imatinib
|
p<0.001
|
Plasma
|
21323568
|
595
|
sVEGFR1
|
Protein
|
Humans
|
Downregulated in Docetaxel + Imatinib arm
|
Predictive
|
Docetaxel + placebo VS Docetaxel + imatinib
|
p=0.001
|
Plasma
|
21323568
|
679
|
miR-141
|
miRNA
|
Humans
|
Upregulated with increasing PSA
|
Prognostic
|
progression Vs No Progression
|
p<0.001
|
Plasma
|
21723797
|
680
|
Circulating Tumor Cells
|
Others
|
Humans
|
Upregulated with increasing PSA
|
Prognostic
|
progression Vs No Progression
|
p=0.002
|
Plasma
|
21723797
|
681
|
Lactate Dehydrogenase (LDH)
|
Metabolites
|
Humans
|
Upregulated with increasing PSA
|
Prognostic
|
progression Vs No Progression
|
p= 0.014
|
Plasma
|
21723797
|
772
|
Thiobarbituric acid reactive substances (TBARS)
|
Protein
|
Humans
|
Upregulated in PCA
|
Diagnostic
|
Controls Vs Patients
|
p<0.05
|
Plasma
|
21993000
|
777
|
Thiobarbituric acid reactive substances (TBARS)
|
Protein
|
Humans
|
Upregulated in Localised and Bone Metastasis
|
Prognostic
|
Controls Vs Localised Vs Bone Metastasis
|
p<0.05
|
Plasma
|
21993000
|
780
|
Thiobarbituric acid reactive substances (TBARS)
|
Protein
|
Humans
|
Upregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.)
|
Prognostic
|
Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A)
|
p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) & PCA (No Treatment) Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A)
|
Plasma
|
21993000
|
783
|
Thiobarbituric acid reactive substances (TBARS)
|
Protein
|
Humans
|
Upregulated in PCA (GS<7, GS=7, GS>7)
|
Prognostic
|
Controls Vs GS<7 Vs GS =7 Vs GS>7
|
p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7)
|
Plasma
|
21993000
|
837
|
mir-107; mir-130b; mir-141; mir-181a-2*; mir-2110; mir-301a; mir-326; mir-331-3p; mir-432; mir-574-3p; mir-625;
|
miRNA
|
Humans
|
Upregulated in PCa: [mir-107; mir-130b; mir-141; mir-2110; mir-301a; mir-326; mir-331-3p; mir-432; mir-574-3p; mir-625;] Downregulated in PCa: [miR-181a-2* (2.69 fold)]
|
Diagnostic
|
Normal Vs prostate cancer
|
p<0.001
|
Plasma
|
22240788
|
838
|
mir-107; mir-141; mir-181a-2*; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625;
|
miRNA
|
Humans
|
Upregulated in localised PCa: [mir-107; mir-141; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625;] Downregulated in localised PCa: [miR-181a-2* (2.69 fold)]
|
Diagnostic
|
Normal Vs localised prostate cancer
|
p<0.001
|
Plasma
|
22240788
|
839
|
mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-572; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b
|
miRNA
|
Humans
|
Upregulated in metastatic PCa: [mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b] Downregulated in metastatic PCa: [miR-572 (7.39 fold)]
|
Diagnostic
|
metastatic prostate cancer Vs localised prostate cancer
|
p<0.001
|
Plasma
|
22240788
|
843
|
let-7c + let-7e+miR30c+ miR-622+ miR1285
|
miRNA
|
Humans
|
Differentially expressed
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
p<0.001
|
Plasma
|
22298030
|
844
|
let-7c + let-7e+miR30c+ miR-622+ miR1285
|
miRNA
|
Humans
|
Differentially expressed
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
p<0.001
|
Plasma
|
22298030
|
845
|
let-7c
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
Testing: p<0.001
|
Plasma
|
22298030
|
846
|
let-7e
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
Testing: p<0.001
|
Plasma
|
22298030
|
847
|
miR-30c
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
Testing: p<0.001
|
Plasma
|
22298030
|
848
|
miR-622
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
Testing: p<0.001
|
Plasma
|
22298030
|
849
|
miR-1285
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
Testing: p=0.0047
|
Plasma
|
22298030
|
850
|
let-7c
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training & Testing: p<0.0001
|
Plasma
|
22298030
|
851
|
let-7e
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p=0.0029; Testing = p<0.0001
|
Plasma
|
22298030
|
852
|
miR-25
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p<0.0001; Not significant in validation set
|
Plasma
|
22298030
|
853
|
miR-30c
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p<0.0001
|
Plasma
|
22298030
|
854
|
miR-346
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p<0.0001; Not significant in validation set
|
Plasma
|
22298030
|
855
|
miR-622
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p<0.0001
|
Plasma
|
22298030
|
856
|
miR-940
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p= 0.0062
|
Plasma
|
22298030
|
857
|
miR-1285
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p<0.0001
|
Plasma
|
22298030
|
858
|
basic fibroblast growth factor (bFGF)
|
Protein
|
Humans
|
Upregulated in Treatment Group: [Treatment: 32 (25–71) Vs Control : 11 (8–14)]
|
Predictive
|
ADT Treatment Vs No Treatment
|
p=0.0006
|
Plasma
|
22302227
|
859
|
Interleukin 1 (IL-1β)
|
Protein
|
Humans
|
Upregulated in Treatment Group [Treatment:0.56 (0.45–0.90) Vs Control : 0.34 (0.25–0.52)]
|
Predictive
|
ADT Treatment Vs No Treatment
|
p=0.026
|
Plasma
|
22302227
|
860
|
Interleukin 8 (IL-8)
|
Protein
|
Humans
|
Upregulated in Treatment Group (Treatment: 5.7 (3.8–7.7) Vs Control : 2.2 (1.6–2.8) )
|
Predictive
|
ADT Treatment Vs No Treatment
|
p=0.0001
|
Plasma
|
22302227
|
861
|
stromal cell–derived factor 1α (SDF-1α)
|
Protein
|
Humans
|
Upregulated in Treatment Group (Treatment: 2,294 (1,775–2,671) Vs Control : 1,736 (1,577–1,842) )
|
Predictive
|
ADT Treatment Vs No Treatment
|
p=0.023
|
Plasma
|
22302227
|
862
|
sphingosine-1-phosphate (S1P)
|
Protein
|
Humans
|
Downregulated in Prostate Cancer (Healthy: 10.36±0.69 ; BPH: 9.39±0.75; PCA: 6.89±0.58)
|
Diagnostic
|
Healthy Controls Vs BPH VS Prostate Cancer
|
p <0.05
|
Plasma
|
22315056
|
863
|
sphingosine-1-phosphate (S1P)
|
Protein
|
Humans
|
Downregulated in Stage 2 PCa than Stage 1 PCa
|
Prognostic
|
Stage 1 Vs Stage 2 prostate cancer
|
p<0.001
|
Plasma
|
22315056
|
864
|
sphingosine-1-phosphate (S1P)
|
Protein
|
Humans
|
Downregulated in Patients with No survival (No Survival: 5.11±0.75 Vs Survival: 7.02±0.22)
|
Prognostic
|
disease specific survival Vs no survival
|
p=0.0439
|
Plasma
|
22315056
|
865
|
Erythrocyte sphingosine kinase-1 (SphK1)
|
Protein
|
Humans
|
Downregulated in PCa (Healthy: 4.7±0.42; PCa: 2.14±0.17)
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
p<0.0001
|
Plasma
|
22315056
|
866
|
Testosterone
|
Protein
|
Humans
|
Downregulated in Gleason Score 8-9
|
Prognostic
|
Gleason Sum 5 Vs Gleason Sum 8-9
|
p=0.0495
|
Plasma
|
22315056
|
867
|
Testosterone
|
Protein
|
Humans
|
Upregulated in Metastases
|
Prognostic
|
Metastases Vs No Metastases
|
p<0.0001
|
Plasma
|
22315056
|
920
|
Deoxycarnitine; Acetylcarnitine; Hexanoylcarnitine; Octanoylcarnitine; Decanoylcarnitine; Laurylcarnitine; Palmitoylcarnitine; Stearoylcarnitine; Oleoylcarnitine; 3-hydroxybutyrate (BHBA); Acetoacetate; Dodecanedioate; Octadecanedioate;
|
Metabolites
|
Humans
|
Differentially expressed [ Deoxycarnitine (0.89 fold); Acetylcarnitine (0.80 fold); Hexanoylcarnitine (0.80 fold_; Octanoylcarnitine (0.72 fold); Decanoylcarnitine (0.71 fold); Laurylcarnitine (0.65 fold); Palmitoylcarnitine (0.82 fold0; Stearoylcarnitine (0.77 fold); Oleoylcarnitine (0.88 fold); 3-hydroxybutyrate (BHBA) (0.36 fold); Acetoacetate (0.52 fold); Dodecanedioate (0.80 fold); Octadecanedioate (0.73 fold);]
|
Predictive
|
Effect of Androgen deprivation therapy (ADT) baseline to 3 months
|
<0.05
|
Plasma
|
22589396
|
932
|
Modification Status of RNF219
|
cirDNA
|
Humans
|
Highly modified in PCa Patients (Control: 55%
|
Diagnostic
|
PCA VS no history of prostate disease
|
p=3 *10^-41
|
Plasma
|
22619380
|
933
|
Modification Status of RNF220
|
cirDNA
|
Humans
|
Highly modified in PCa Patients (Control: 55%
|
Diagnostic
|
PCA Vs BPH
|
p = 1 *10^-4
|
Plasma
|
22619380
|
967
|
Osteopontin
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs BPH VS Healthy Donors
|
p<0.05
|
Plasma
|
22870138
|
1012
|
Survivn
|
Protein
|
Humans
|
Upregulated in PCA compared to both Healthy controls and BPH
|
Diagnostic
|
(Normal and BPH )VS PCa
|
p<0.001
|
Plasma
|
23091600
|
1018
|
sICAM-1
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 245.2 , Normal: 240.3)
|
Diagnostic
|
PCa Vs Controls
|
p=0.005
|
Plasma
|
23171880
|
1019
|
CRP
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 2.5 , Normal: 2.1)
|
Diagnostic
|
PCa Vs Controls
|
[Odds Ratio: p=0.03]; [Regulation: p = 0.006]
|
Plasma
|
23171880
|
1027
|
Carbonic Anhydrase I
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCA Vs Healthy Controls
|
p = 0.022
|
Plasma
|
23213568
|
1028
|
PSA + Carbonic Anhydrase I
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCA Vs Healthy Controls
|
p = 0.022
|
Plasma
|
23213568
|
1091
|
miR-141
|
miRNA
|
Humans
|
Upregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1092
|
miR-375
|
miRNA
|
Humans
|
Upregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1093
|
miR-151-3p
|
miRNA
|
Humans
|
Upregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1094
|
miR-126
|
miRNA
|
Humans
|
Upregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1095
|
miR-16
|
miRNA
|
Humans
|
Downregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1096
|
miR-205
|
miRNA
|
Humans
|
Downregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1097
|
PSA + miR141 + mir-151-3p + mir-16
|
miRNA
|
Humans
|
Upregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1098
|
miR-423-3p
|
miRNA
|
Humans
|
Upregulated with High Gleason Score
|
Prognostic
|
Gleason Score < 7 Vs Gleason Score ≥ 8
|
p = 0.002
|
Plasma
|
23574937
|
1099
|
miR-205
|
miRNA
|
Humans
|
Downregulated with High Gleason Score
|
Prognostic
|
Gleason Score < 7 Vs Gleason Score ≥ 8
|
p = 0.004
|
Plasma
|
23574937
|
1100
|
miR-205
|
miRNA
|
Humans
|
Upregulated in Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence
|
p = 0.006
|
Plasma
|
23574937
|
1101
|
miR-423-3p
|
miRNA
|
Humans
|
Downregulated in Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence
|
p<0.001
|
Plasma
|
23574937
|
1102
|
miR-151-3p
|
miRNA
|
Humans
|
Downregulated in Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence
|
p<0.001
|
Plasma
|
23574937
|
1156
|
Peptide ID: 3495; 3506; 3621; 3992; 4437; 4679; 4697; 5180; 6832; 7661; 8698; 9483; 9645; 10502; 11899; 12083; 13995; 14592; 15331; 18990; 19773]
|
Protein
|
Humans
|
Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: []
|
Diagnostic
|
Prostate Cancer and Benign Prostatic Hyperplasia Vs inflammatory and healthy prostate
|
p< 0.0137
|
Plasma
|
23826311
|
1157
|
Peptide ID: [7098; 8863; 9673; 10706; 24050]
|
Protein
|
Humans
|
Downregulated in PCa [mean(control)/mean (case)]: [Peptide ID: [7098 (3.3 fold) ; 8863 (7.7 fold) ; 9673(73.1 fold) ; 10706 (124.8 fold) ; 24050( 11.1 fold)]
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p< 0.0027
|
Plasma
|
23826311
|
1158
|
21PP + 5PP
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p=0.0001
|
Plasma
|
23826311
|
1159
|
Peptide ID: [1004; 2663; 5650; 7228; 9483; 9504; 10193; 10442; 10471; 10502; 17993]
|
Protein
|
Humans
|
Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: []
|
Prognostic
|
Localised Vs Advanced Prostate Cancer
|
p=0.0055
|
Plasma
|
23826311
|
1206
|
Neuropeptideâ€Y (NPY)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs (Normal and BPH patients)
|
p = 0.0396
|
Plasma
|
23991666
|
1207
|
Neuropeptideâ€Y (NPY) + Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs (Normal and BPH patients)
|
p = 0.0396
|
Plasma
|
23991666
|
1248
|
Thrombospondin-1 [TSP-1]
|
Protein
|
Humans
|
Increased levels indicate better overall survival in Tasquinimod arm
|
Predictive
|
Overall Survival in Tasquinimod Vs Overall Survival in Placebo arm
|
p=0.034
|
Plasma
|
24255071
|
1331
|
UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level
|
mRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
NA
|
Urine + Plasma
|
24512523
|
1332
|
UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score <7 Vs Gleason Score ≥ 7
|
NA
|
Urine + Plasma
|
24512523
|
1393
|
Testosterone
|
Hormone
|
Humans
|
Increased levels in patients with Higher overall Survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.018
|
Plasma
|
24722180
|
1394
|
Testosterone
|
Hormone
|
Humans
|
Lower levels in Non Responders
|
Predictive
|
PSA Responders Vs Non Responder
|
p=0.0196
|
Plasma
|
24722180
|
1496
|
miR-1290
|
miRNA
|
Humans
|
NA
|
Prognostic
|
High Risk vs Low Risk (Survival)
|
p<0.0008
|
Plasma
|
25129854
|
1497
|
miR-1246
|
miRNA
|
Humans
|
NA
|
Prognostic
|
High Risk vs Low Risk (Survival)
|
p<0.0008
|
Plasma
|
25129854
|
1498
|
miR-375
|
miRNA
|
Humans
|
NA
|
Prognostic
|
High Risk vs Low Risk (Survival)
|
p<0.0008
|
Plasma
|
25129854
|
1499
|
miR-1290 + miR-375 + PSA + ADT
|
miRNA
|
Humans
|
NA
|
Prognostic
|
High Risk vs Low Risk (Survival)
|
p= 0.0016
|
Plasma
|
25129854
|
1500
|
miR-1290 + miR-375
|
miRNA
|
Humans
|
NA
|
Prognostic
|
High Risk vs Low Risk (Survival)
|
p<0.05
|
Plasma
|
25129854
|
1509
|
Base model (Age and total PSA)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Plasma
|
25151013
|
1510
|
Four-kallikrein panel (Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA])
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.0001
|
Plasma
|
25151013
|
1511
|
Prostate Health Index (PHI)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.0001
|
Plasma
|
25151013
|
1512
|
Base model (Age and total PSA)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
High-grade Prostate cancer
|
NA
|
Plasma
|
25151013
|
1513
|
Four-kallikrein panel (Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA])
|
Protein
|
Humans
|
NA
|
Diagnostic
|
High-grade Prostate cancer
|
p<0.0001
|
Plasma
|
25151013
|
1514
|
Prostate Health Index (PHI)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
High-grade Prostate cancer
|
p<0.0001
|
Plasma
|
25151013
|
1604
|
Full Length Androgen Receptor (AR-FL)
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Progression-free survival Vs No Progression-free survival
|
p=0.0003
|
Plasma
|
31055861
|
1655
|
miRâ€28; miRâ€100; miRâ€942; miRâ€28â€3p
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Low Grade Vs High Grade Prostate Cancer
|
miRâ€28: p=0.016; miRâ€100: p=0.025; miRâ€942: p=0.025; miRâ€28â€3p: p=0.038
|
Plasma
|
30958910
|
1656
|
miRâ€708; miRâ€1298; miRâ€886â€3p; miRâ€374; miRâ€376c; miRâ€202; miRâ€128a; miRâ€185
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Low Grade Vs High Grade Prostate Cancer
|
miRâ€708: p<0.001; miRâ€1298: p=0.001; miRâ€886â€3p:p=0.01; miRâ€374:p=0.017; miRâ€376c: p=0.031; miRâ€202: p=0.035; miRâ€128a: p=0.039; miRâ€185: p=0.041
|
Plasma
|
30958910
|
2025
|
LPC(18∶1)
|
Metabolites
|
Humans
|
Methylated in systemic Recurrence
|
Diagnostic
|
Patients Vs Controls
|
2.63E-09
|
Plasma
|
23152813
|
2026
|
LPC(20∶4)
|
Metabolites
|
Humans
|
Methylated in systemic Recurrence
|
Diagnostic
|
Patients Vs Controls
|
1.71E-15
|
Plasma
|
23152813
|
2027
|
PC(40∶7)
|
Metabolites
|
Humans
|
Methylated in systemic Recurrence
|
Diagnostic
|
Patients Vs Controls
|
4.37E-11
|
Plasma
|
23152813
|
2028
|
LPC(18∶0)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.7
|
Diagnostic
|
Patients Vs Controls
|
3.00E-08
|
Plasma
|
23152813
|
2029
|
LPC(16∶0)
|
Metabolites
|
Humans
|
Upregulated with fold change of 3.2
|
Diagnostic
|
Patients Vs Controls
|
2.03E-06
|
Plasma
|
23152813
|
2030
|
ePC(38∶4)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.2
|
Diagnostic
|
Patients Vs Controls
|
3.01E-08
|
Plasma
|
23152813
|
2031
|
PC(38∶4)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.5
|
Diagnostic
|
Patients Vs Controls
|
3.65E-05
|
Plasma
|
23152813
|
2032
|
PC(38∶5)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.8
|
Diagnostic
|
Patients Vs Controls
|
8.50E-06
|
Plasma
|
23152813
|
2033
|
SM(18∶1)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.1
|
Diagnostic
|
Patients Vs Controls
|
1.05E-09
|
Plasma
|
23152813
|
2034
|
SM(16∶1)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.1
|
Diagnostic
|
Patients Vs Controls
|
6.71E-09
|
Plasma
|
23152813
|
2035
|
DSM(16∶0)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.2
|
Diagnostic
|
Patients Vs Controls
|
3.85E-19
|
Plasma
|
23152813
|
2036
|
SM(16∶0)
|
Metabolites
|
Humans
|
Upregulated with fold change of 3
|
Diagnostic
|
Patients Vs Controls
|
1.20E-06
|
Plasma
|
23152813
|
2037
|
ePC(36∶1)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.5
|
Diagnostic
|
Patients Vs Controls
|
6.30E-10
|
Plasma
|
23152813
|
2038
|
SM(18∶0)
|
Metabolites
|
Humans
|
Upregulated with fold change of 22.7
|
Diagnostic
|
Patients Vs Controls
|
1.72E-06
|
Plasma
|
23152813
|
2039
|
ePC(36∶2)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.5
|
Diagnostic
|
Patients Vs Controls
|
1.72E-07
|
Plasma
|
23152813
|
2040
|
LPC(18:1)+LPC(20:4)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.4
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2041
|
LPC(18:1)+LPC(20:4)+PC(40:7)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.8
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2042
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2043
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 2
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2044
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 3
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2045
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 4
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2046
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 5
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2047
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 6
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2048
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 7
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2049
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 8
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2050
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 9
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2051
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)+ePC(36:1)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 10
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2052
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)+ePC(36:1)+SM(18:0)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 11
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2053
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)+ePC(36:1)+SM(18:0)+ePC(36:2)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 12
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|